Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +16.00p +6.67% 256.00p 252.00p 256.00p 256.00p 240.00p 240.00p 589,129 16:35:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 200

Silence Therapeutics Share Discussion Threads

Showing 50326 to 50349 of 50825 messages
Chat Pages: Latest  2021  2020  2019  2018  2017  2016  2015  2014  2013  2012  2011  2010  Older
DateSubjectAuthorDiscuss
11/7/2018
07:18
Good to see the Phase 3 AKI trial has finally made it to an rns. I was beginning to think they weren't going to bother.
1gw
06/7/2018
14:08
After many years absence I bought a few over the last few days. Doesn't take much to move. My reasoning for buying now is less what SLN are doing (very little over the years) but that the combination of new blood and more particularly Alnylam's trail progress. My 'hope' is that they make SLN disputes go away by buying them out. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis htTps://www.nejm.org/doi/full/10.1056/NEJMoa1716153
waterloo01
06/7/2018
13:00
Seems like a good bounce for such low volume. Still, not complaining.
1gw
20/6/2018
21:50
Thanks callumross. She looks pretty full-on, i.e. fully engaged in what Silence is doing - so that's good. She presented Ali's departure as a Silence-led thing - time for a person with a different skillset to take over now that Ali had got the company capitalised and largely staffed up. She didn't strike me as someone who thought she was in the executive role purely in an interim capacity. I thought she was going to go the whole interview without mentioning the patent litigation but did comment when prompted towards the end. Sounds like we should expect to hear some news on a "partnership" before too long - i.e. another company licensing or in some other way coming on board the Silence platform. Let's hope so. And good to see that the Nasdaq listing and other shareholder-pleasing moves are still under consideration.
1gw
20/6/2018
16:09
Interesting Callum
volsung
20/6/2018
13:44
http://www.proactiveinvestors.co.uk/companies/stocktube/9554/silence-therapeutics-in-a-hot-space-with-few-competitors--9554.html
callumross
04/6/2018
22:11
I see it as either he's decided that he's done all he can & is now following a more promising/interesting avenueOrThere's something interesting short term brewing.Whatever. I said to myself when he or gang lost interest I was out but I am currently intrigued. I may well pay for that view
djnzloop
04/6/2018
21:44
Very strange shareprice move given the news. Good volume for recent months, but pretty small as a % of the share capital. I can't see that losing Ali in such an apparently unplanned way is at all positive. I presume he had a lot to do with the strategy around both the ARWR stake and the patent litigation, and although ARWR was successfully disposed of, the patent litigation / negotiation could have a long way still to run. So I wonder if it was an existing shareholder deciding to buy back having previously sold some in anticipation of something along these lines happening. Because it's equally unclear to me why the price should have fallen so quickly from its £2 base in the first place. While I did wonder when her appointment as (non-exec) Chair was announced if Annalisa Jenkins was being lined up for an executive role at Silence once the Dimension sale was finished, she was snapped up by Plaquetec in November (link below). I don't see how she can successfully combine the roles of Plaquetec CEO and Silence Executive Chair for long (is Plaquetec going to be compensated if she has to go part-time there for a while?), so perhaps she thinks Silence is close to landing a good candidate for the CEO role. Unless of course, Ali going is the price of closing a deal with Alny or someone else, and everyone involved knows who is going to be in charge when the deal does close - but that seems a bit far-fetched. hTtps://www.prnewswire.com/news-releases/plaquetec-announces-the-appointment-of-annalisa-jenkins-mbbs-frcp-as-chief-executive-officer-657181603.html
1gw
04/6/2018
12:26
Or if Ali sells on his stake, to whom?
callumross
04/6/2018
12:20
Perhaps the fall from 200p was due at least in part to some selling on a rumour of this event? And now we're getting some buying on the news?
1gw
04/6/2018
12:02
Wonder why the shares have jumped 9% on this announcement?
callumross
04/6/2018
11:49
Unlikely re an offer and more likely that they have rather lost their way in putting most effort onto legal cases with little else actually happening.
waterloo01
04/6/2018
10:46
Is this a prelude to an offer being made?
mirabeau
01/6/2018
19:01
In April the status of the trial was "not recruiting yet"
callumross
01/6/2018
19:01
Study completion date for AKI phase 3 is 3 years away though!
callumross
01/6/2018
18:38
In fact, this is what Silence said in the annual report about QPI-1002 / AKI: "Silence awaits news from Quark as to the next steps in development of QPI-1002 in AKI." So that sounds to me like they might well consider a release when they get or notice the news...
1gw
01/6/2018
18:35
Interesting. Might there be a Silence release on that then, if not a milestone payment? This is what they put out when Phase 2 concluded successfully. hTtp://www.silence-therapeutics.com/media/1691/rns-quark-aki-results-270717.pdf A further release couldn't hurt sentiment, which appears in need of a bit of a boost. Not quick are they these phase 3 studies? DGF started in December 2015 as far as I can see, and is due to conclude June (Primary completion) / December (study completion) next year. hTtps://clinicaltrials.gov/ct2/show/NCT02610296
1gw
01/6/2018
16:27
Just noticed that Quark have put QPI-1002 into phase 3 trials for AKI; https://clinicaltrials.gov/ct2/show/NCT03510897 It has been in phase 3 for a while for DGF
callumross
31/5/2018
15:39
And buying some more today at 142p. While clearly high risk as a biotech investment, I like Silence over the next 1-2 years for: - 2 programmes moving towards clinical development (late 2018 and 1H 2019) - things potentially coming to a head with Alnylam (High Court on, or around, 3rd Dec) - Positive sentiment elsewhere in the sector (cf ARWR) - Objective to secure further strategic collaboration / out-licensing in 2018 - Potential for Nasdaq listing - Concentrated shareholder base (RG,RK, Invesco)
1gw
24/5/2018
12:32
All gone very quiet over here, waiting for news on the patent battle I suppose. ARWR continues to fly (wish I had held on a bit longer) while ALNY has dropped back significantly from its recent high. Anyway, I've bought some more Silence today at 153p, hoping the shareprice can bounce from around this level.
1gw
21/4/2018
15:10
Hmmm. Allows Alny to focus a bit more on Silence then. AGM on Monday.
1gw
20/4/2018
18:00
htTps://www.businesswire.com/news/home/20180420005589/en/Dicerna-Pharmaceuticals-Announces-Settlement-Litigation-Alnylam
waterloo01
06/4/2018
05:43
Well that jolted the calm seas of the first quarter then! Court action not until December I believe, so unless there's unexpected good news in the meantime a drift down for a while?
ukeagle2aus
03/4/2018
10:38
The hope is that ALYN will at some point find it easier to buy them than fight in court, but little evidence of that to date, just years ahead of suit/counter suit and money to the lawyers and very little actual scientific progress.
waterloo01
Chat Pages: Latest  2021  2020  2019  2018  2017  2016  2015  2014  2013  2012  2011  2010  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191020 21:10:12